The SARS-CoV-2 pandemic significantly affected oncology practice across the globe. There is uncertainty as to the contribution of patients\u2019 demographics and oncologic features to severity and mortality from COVID-19 and little guidance as to the role of anticancer and anti\u2013COVID-19 therapy in this population.<\/p>\n
In order to look for associations between severity and mortality from COVID-19 and patients\u2019 demographics, oncologic features and cancer terapies, we conducted a multicenter, observational study of 890 patients with cancer and confirmed COVID-19.<\/p>\n
We demonstrated a worsening gradient of mortality from breast cancer to hematologic malignancies and showed that male gender, older age, and number of comorbidities identify a subset of patients with significantly worse mortality rates from COVID-19. Provision of chemotherapy, targeted therapy, or immunotherapy did not worsen mortality. Exposure to antimalarials was associated with improved mortality rates independent of baseline prognostic factors.<\/p>\n
In this observational study of 890 patients with cancer diagnosed with SARS-CoV-2, mortality was 33.6% and predicted by male gender, age \u226565, and comorbidity burden. Delivery of cancer therapy was not detrimental to severity or mortality from COVID-19. Hence, this study highlights the clinical utility of demographic factors for individualized risk stratification of patients and supports further research into emerging anti\u2013COVID-19 therapeutics in SARS-CoV-2\u2013infected patients with cancer.<\/p>\n","protected":false},"template":"","categoria-pubblicazioni":[5056],"class_list":["post-8963","pubblicazione","type-pubblicazione","status-publish","hentry","categoria-pubblicazioni-onco-aging"],"yoast_head":"\n